|
業務類別
|
-- |
|
業務概覽
|
NIOX Group PLC is engaged in improving the diagnosis, monitoring and management of both asthma and COPD by providing greater patient access to FeNO testing. The company is engaged in the design, development, and commercialization of medical devices for the measurement of FeNO, a precise biomarker for type 2 inflammation which is present in asthma and COPD. Its device, NIOX VERO, is increasingly recognised by healthcare professionals as an important tool to improve the diagnosis, monitoring and management of asthma and COPD. It operates in single segment of NIOX relates to the portfolio of products used to improve asthma diagnosis, monitoring and management by measuring fractional exhaled nitric oxide (FeNO). |
| 公司地址
| 1 Robert Robinson Avenue, The Magdalen Centre, The Oxford Science Park, Oxford, GBR, OX4 4GA |
| 電話號碼
| +44 3303309356 |
| 傳真號碼
| +44 7092987560 |
| 公司網頁
| https://www.niox.com |
| 員工數量
| 90 |
| Ms. Sarah Elizabeth Duncan |
Executive Director,Chief Financial Officer |
英鎊 104.00K |
21/04/2026 |
| Ms. Rebecca Clayton-Wherity |
Company Secretary |
-- |
21/04/2026 |
| Mr. Jonathan Charles Emms |
Executive Director,Chief Executive Officer |
英鎊 397.00K |
21/04/2026 |
|
|
| Ms. Sarah Elizabeth Duncan |
Executive Director,Chief Financial Officer |
21/04/2026 |
| Mr. Ian Roy Johnson |
Non-Executive Director,Chairman |
21/04/2026 |
| Ms. Sharon Evelyn Curran |
Non-Executive Director |
21/04/2026 |
| Mr. Jonathan Charles Emms |
Executive Director,Chief Executive Officer |
21/04/2026 |
| Mr. Nicholas Harwood Bertram Mills |
Non-Executive Director |
21/04/2026 |
| Mr. Robert Graham Naylor |
Non-Executive Director |
21/04/2026 |
| Mr. Garry Watts MBE |
Non-Executive Director,Senior Independent Director |
21/04/2026 |
|
|
|
|
